Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis.
cisplatin
hepatic arterial infusion chemotherapy
hepatocellular carcinoma
multikinase inhibitor
propensity score-matched analysis
risk factors
sorafenib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Oct 2021
21 Oct 2021
Historique:
received:
23
09
2021
revised:
16
10
2021
accepted:
18
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
Given that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin versus sorafenib for intrahepatic advanced HCC using propensity score-matched analysis. We enrolled 331 patients with intrahepatic advanced HCC who received HAIC with cisplatin (n = 88) or sorafenib (n = 243) between June 2006 and March 2020. No significant difference was observed in OS between HAIC with cisplatin and sorafenib cohorts (median survival time [MST]: 14.0 vs. 12.3 months;
Identifiants
pubmed: 34771452
pii: cancers13215282
doi: 10.3390/cancers13215282
pmc: PMC8582478
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Medicine (Baltimore). 2018 Apr;97(17):e0611
pubmed: 29703062
J Hepatol. 2020 Feb;72(2):250-261
pubmed: 31954490
Liver Cancer. 2015 Sep;4(3):188-99
pubmed: 26674592
Semin Liver Dis. 2010 Feb;30(1):61-74
pubmed: 20175034
Ann Surg Oncol. 2021 Dec;28(13):8174-8185
pubmed: 34409542
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Liver Cancer. 2020 Sep;9(5):583-595
pubmed: 33083282
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432
pubmed: 29631810
Hepatol Res. 2019 Oct;49(10):1109-1113
pubmed: 31336394
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Rheum Dis Clin North Am. 2018 May;44(2):203-213
pubmed: 29622292
J Hepatol. 2001 Sep;35(3):421-30
pubmed: 11592607
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Anticancer Res. 2019 Jul;39(7):3909-3916
pubmed: 31262920
Clin Mol Hepatol. 2019 Dec;25(4):381-389
pubmed: 31405269
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Stat Med. 1998 Oct 15;17(19):2265-81
pubmed: 9802183
Eur J Surg Oncol. 2021 Aug 13;:
pubmed: 34452770
AJR Am J Roentgenol. 2021 Jun;216(6):1566-1573
pubmed: 33852336
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Jpn J Clin Oncol. 2019 Sep 1;49(9):845-855
pubmed: 31063184
JAMA Oncol. 2019 Jul 1;5(7):953-960
pubmed: 31070690
Semin Diagn Pathol. 2017 Mar;34(2):153-159
pubmed: 28108047
Surg Oncol. 2016 Jun;25(2):74-85
pubmed: 27312032
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
J Gastroenterol Hepatol. 2018 Oct;33(10):1780-1786
pubmed: 29645345
J Hepatol. 2018 Jul;69(1):60-69
pubmed: 29471013
Cancers (Basel). 2021 Feb 05;13(4):
pubmed: 33562793
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Stat Med. 2013 Jul 20;32(16):2837-49
pubmed: 23239115
Ann Oncol. 2016 Nov;27(11):2090-2096
pubmed: 27573564